CX Institutional’s Jazz Pharmaceuticals JAZZ Stock Holding History

CX Institutional’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.12M	Sell	9,168 -48	-0.5%	-$11.9K	0.06%	246
2026 Q2	$2.22M	Sell	9,216 -390	-4%	-$85.4K	0.06%	241
2026 Q1	$1.82M	Sell	9,606 -1,226	-11%	-$214K	0.06%	265
2025 Q4	$1.84M	Sell	10,832 -50,355	-82%	-$7.72M	0.05%	210
2025 Q3	$8.06M	Buy	61,187 +18,295	+43%	+$2.19M	0.24%	100
2025 Q2	$4.55M	Buy	42,892 +8,124	+23%	+$882K	0.16%	144
2025 Q1	$4.32M	Buy	+34,768	New	+$4.54M	0.16%	132
2019 Q3	–	Sell	-7	Closed	-$1K	–	877
2019 Q2	$1K	Buy	+7	New	+$941	﹤0.01%	861

Other funds holding JAZZ

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

Polaris Capital Management Boston, Massachusetts $953M AUM 27.74% 1-Year Est. Return

Argent Capital Management St Louis, Missouri $3.14B AUM 31.36% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return

Perpetual Ltd Sydney, New South Wales, Australia $6.57B AUM 14.15% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

CX Institutional's JAZZ Position: Q3 2026 in Review

CX Institutional reduced its Jazz Pharmaceuticals (JAZZ) stake by 0.52% in Q3 2026, selling an estimated $11.9K and leaving 9,168 shares worth $2.12M. The position accounts for 0.06% of the portfolio, ranked #246.

CX Institutional first reported a position in JAZZ in Q2 2019 and has held it in 8 quarters since. The position peaked at $8.06M in Q3 2025. 127 funds tracked by Wall St. Rank hold JAZZ as of Q3 2026.

CX Institutional held 9,168 shares of Jazz Pharmaceuticals worth $2.12M as of Q3 2026.
CX Institutional sold 48 Jazz Pharmaceuticals shares in Q3 2026, an estimated $11.9K.
Jazz Pharmaceuticals made up 0.06% of CX Institutional's portfolio in Q3 2026, its #246 holding.
CX Institutional first reported a position in Jazz Pharmaceuticals in Q2 2019 and has held it in 8 quarters since.
CX Institutional's Jazz Pharmaceuticals position peaked at $8.06M in Q3 2025.
127 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2026.

Based on CX Institutional's 13F filing for Q3 2026, filed 2 Oct 2026.